Tag:
R788
Latest Headlines
Latest Headlines
AZ pushes pedal to metal on PhIII oral RA blitzkrieg
Just six months after AstraZeneca paid $100 million upfront to grab the licensing rights to Rigel's promising oral rheumatoid arthritis therapy , the pharma giant is ramping up a slate of late-stage
AZ/Rigel RA drug hits PhIIb paydirt
AstraZeneca's $100 million upfront wager on Rigel's experimental rheumatoid arthritis therapy R788 has paid off with a promising set of mid-stage data just as the partners prepare for their Phase III
Rigel RA drug flunks Phase II trial
Shares of Rigel Pharmaceuticals were hit hard this morning as the company's rheumatoid arthritis drug R788 failed a mid-stage trial in patients who did not respond to at least one biologic treatment.
Positive RA study sets stage for lucrative Rigel pact
A second mid-stage study has turned up positive data for Rigel's experimental treatment for rheumatoid arthritis. And execs for the developer say they're closing in on a partnership deal that they
Rigel slices staff as it waits for IIb data
Rigel Pharmaceuticals has cut 20 percent of its staff and shelved some of its research work while opting to delay any partnership talks until it gets crucial Phase IIb data on its rheumatoid
Rigel shares sink on arthritis drug concerns
Shares of South San Francisco-based Rigel dropped 38 percent Monday after the company reported Phase IIa results of arthritis drug R788. There was a disparity between results in patients tested in
